Newsbenzinga
These Analysts Increase Their Forecasts On Gilead Sciences After Upbeat Q3 Results
· Published
Article summary
Gilead beats Q3 estimates, raises 2026 sales guidance but cuts EPS outlook; shares rise 4.1% as analysts lift price targets.
An excerpt from the original article.
Comments —
Loading comments…